Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine - Regeneron Pharmaceuticals (NASDAQ:REGN)
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM - Regeneron Pharmaceuticals (NASDAQ:REGN)